Hims & Hers Stock Plunges Amid Strategic Pivot and Security Breach

Hims & Hers stock nears 52-week low due to weight-loss strategy pivot, cybersecurity breach, and CFO share sales. The company faces lower profit margins and legal probes while pursuing growth via acquisition.

Shares of telehealth provider Hims & Hers have tumbled 37% year-to-date, trading near a 52-week low of $13.74. This steep decline reflects a confluence of operational challenges, including a major strategic shift in its weight-loss business, a significant data breach, and substantial insider selling by its finance chief.

The company is fundamentally restructuring its lucrative weight management segment. It is discontinuing the sale of its own compounded GLP-1 medications and will instead offer expensive, branded drugs like Novo Nordisk's Wegovy and Ozempic. While this move resolves an earlier legal dispute with Novo Nordisk, analysts warn it carries a major drawback: selling branded pharmaceuticals typically yields significantly lower profit margins than the previous in-house mixtures.

This strategic pivot arrives alongside heightened legal scrutiny. Several US law firms are investigating potential securities fraud, focusing on statements related to the FDA's plans to more strictly regulate compounded GLP-1 drugs. Bank of America has cut its price target on the stock from $23 to $21, fearing the EBITDA contribution from the GLP-1 business could drop by up to 50% this year. Overall, 2026 profit expectations are now roughly 21% below prior market estimates.

Investor confidence has been further shaken by a cybersecurity incident. Between February 4 and 7, unauthorized parties gained access to a third-party customer service platform. Although medical records and doctor communications were untouched, names and contact details were exposed. The company began notifying affected users in early April and reported the incident to California authorities. The breach has sparked potential class-action lawsuits, raising fears of regulatory and financial repercussions.

Compounding these issues, Chief Financial Officer Oluyemi Okupe is selling a large block of shares. On April 6, he sold a first package worth nearly $80,000. More significantly, he has filed to sell over 240,000 additional shares valued at approximately $4.9 million. While these transactions are based on a trading plan established in May 2025, the optics are poor given the current turbulent backdrop for the company.

Despite these headwinds, management is pushing forward with an ambitious growth plan. A key element is the pending $1.15 billion acquisition of Australian provider Eucalyptus Health, expected to close mid-year. This deal will add about 775,000 new customers and bolster the company's presence in markets like the UK, Germany, and Japan, integrating with its existing base of 2.5 million subscribers.

The company has also outlined specific financial targets. For 2026, it forecasts revenue between $2.7 billion and $2.9 billion, with adjusted EBITDA projected from $300 million to $375 million. Its long-term goal is to achieve at least $6.5 billion in revenue by 2030.

To hit these marks, Hims & Hers must successfully navigate two parallel operational hurdles. Its new branded subscription service, priced from $39 per month, must offset thinner margins with substantially higher volume. Simultaneously, it must smoothly integrate the massive Eucalyptus acquisition. With the stock down 66% over the past six months, the path to recovery remains fraught with both strategic and reputational challenges.